Document:

Exhibit 4.10

 

Execution Copy

 

RESTATED AGREEMENT
TO

REPAY INDIVIDUAL
LOAN

 

THE
AGREEMENT TO REPAY AN INDIVIDUAL LOAN (the “Agreement”) that was initially entered into on the 5th of
February, 2020 is RESTATED this 13th day of June, 2020 (the “Effective Date”), into by and between Inhibikase
Therapeutics, Inc., a Delaware corporation (“Corporation”) and Milton H. Werner, Ph.D., individually a resident of
the State of Georgia (“the Individual“).

 

1.             Corporation Loan.

 

		(a)	The Amount. The Individual will loan the Corporation a principal
amount of $248,911. The date of the funding of such loan is the Loan Issue Date.

 

		(b)	Terms of Repayment. The principal amount of Individual Loan is to
be repaid by Corporation, either in full or in part until paid in full, as the case may be, without demand and in immediately available
funds, in lump sum on the earlier to occur of either (i) the thirtieth (30th) month following the Loan Issue Date or
(ii) the date on which the Corporation has sufficient funds to repay the Individual Loan (together, the “Maturity Date”);

 

		(c)	Interest. From and including the Loan Issue Date to and including
the Maturity Date, the Individual Loan shall bear simple interest at current Federal Funds rate of 0.25%, compounded semi-annually.
Such interest shall be payable on the Maturity Date.

 

		(d)	Tender. All payments of principal and interest shall be made in lawful
money of the United States of America and shall be made by Corporation via wire transfer to an account designated by the Individual
or, if no account is so designated, at the Individual’s address set forth in Section 5 or at such other place as the Individual
may designate in writing.

 

		(e)	Right of Prepayment; Allocation. Corporation shall have the right
to repay the Individual Loan at any time during the term hereof without penalty. Any payments received by the Individual hereunder
shall be applied as follows: first, to any costs and expenses due to Individual hereunder; second, to accrued but unpaid interest
hereon; and third, to pay the unpaid principal balance hereunder.

 

2.             Events of Default. The occurrence or existence of any one of the following events or conditions shall constitute
an “Event of Default”:

 

(a)         Corporation shall fail to pay the principal of, or interest on, Individual Loan when the same becomes due and payable in
accordance with the terms hereof and such amount remains unpaid for ten (10) business days after the due date thereof; or

 

(b)         Corporation
makes a general assignment for the benefit of its creditors or applies to any tribunal for the appointment of a trustee or
receiver of a substantial part of the assets of Corporation, or commences any proceedings relating to Corporation under any
bankruptcy, reorganization, arrangement, insolvency, readjustment of debts, dissolution or other liquidation law of any
jurisdiction; or any such application is filed, or any such proceedings are commenced against Corporation and Corporation
indicates its consent to such proceedings, or an order or decree is entered by a court of competent jurisdiction appointing
such trustee or receiver, or adjudicating Corporation bankrupt or insolvent, or approving the petition in any such
proceedings, and such order or decree remains in effect for ninety (90) days.

 

    	Restated Corporation Loan to Werner
	1 

    

    

 

Execution Copy

 

3.            Remedies. If an Event of Default occurs and is continuing, Individual may, by notice in writing to Corporation,
declare the entire unpaid principal of Individual Loan to be due and payable immediately. The Corporation agrees to issue a Warrant
to purchase the number of shares equal to 150% the value of the loan at an individual share price of $4.81 in the case of any default.
In the Event of a Default, the Warrant will remain in effect even after the loan is repaid.

 

4.            Expenses. Except as otherwise provided in this Individual Loan, Employee and Corporation shall bear its own costs
incurred in connection with the negotiation, documentation and execution of this Individual Loan, the closing of the transactions
contemplated herein, and any amendment, waiver, consent, supplement or modification hereto.

 

5.            Notices. All notices, requests, consents and other communications required or permitted under this Indivual Loan
shall be in writing and shall be deemed to have been delivered three (3) days after the date mailed, postage prepaid, by certified
mail, return receipt requested, or on the date personally delivered:

 

	If to Corporation, to:	If to Individual, to: 
	 	 
	Inhibikase
Therapeutics, LLC 

Attn: Chief Executive

3350 Riverwood Parkway, Suite 1900

Atlanta, GA 30339	Milton H. Werner, PhD

874 Birds ML SE

Marietta, GA 30067  

 

Individual and Corporation may designate a different address by notice given in accordance with the foregoing.

 

6.            Individual’s Representations and Warranties. Individual hereby represents and warrants to Corporation that
the statements contained in this Section are true, correct and complete as of the date of this Individual Loan: (a) Individual
is a resident of the State of Georgia; (b) Individual has full power and authority (including full corporate power and authority)
to execute and deliver this Individual Loan and to perform its obligations hereunder; (c) this Individual Loan constitutes the
valid and legally binding obligation of Corporation, enforceable in accordance with its terms and conditions; (d) the execution,
delivery and performance of this Individual Loan and all other agreements contemplated hereby have been duly authorized by Corporation;
(e) neither the execution and delivery of this Individual Loan, nor the consummation of the transactions contemplated hereby, will
(i) violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction
of any government, governmental agency, or court to which Individual is subject or any provision of its charter, bylaws, or other
governing documents, (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create
in any party the right to accelerate, terminate, modify, or cancel, or require any notice under any agreement, contract, lease,
license, instrument, or other arrangement to which Individual is a party or by which it is bound or to which any of its assets
is subject, (iii) result in the imposition or creation of a lien upon or with respect to its assets or (iv) require the prior written
consent of any third party.

 

7.            Waiver and Agreement. Any provision of this Individual Loan may be amended, waived or modified upon the written
consent of Individual and Corporation.

 

8.            Assignment;
Binding Effect. Corporation shall not be entitled to assign all or any portion of its performance obligations under
this Individual Loan and any attempted assignment hereof shall be void and of no effect. Individual may assign this
Individual Loan and its right to receive payment hereunder. Subject to the preceding sentences, this Individual Loan shall be
binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators,
successors and assigns.

 

    	Restated Corporation Loan to Werner
	2 

    

    

 

Execution Copy

 

9.            Governing Law and Waiver of Jury Trial. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF GEORGIA WITHOUT GIVING EFFECT TO CONFLICTS OF LAWS PRINCIPLES. THE PARTIES HERETO WAIVE ALL RIGHTS TO
TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE, WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE
BETWEEN THE PARTIES ARISING OUT OF, CONNECTED WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION
WITH THIS AGREEMENT OR MATTERS RELATED HERETO.

 

10.          Venue. MAKER
HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE JURISDICTION OF THE COURTS OF THE STATE
OF GEORGIA SITTING IN COBB COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE DISTRICT OF GEORGIA, AND ANY APPELLATE COURT
FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT
OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF
ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH STATE OR, TO THE EXTENT PERMITTED BY LAW, IN SUCH FEDERAL
COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY
BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT
SHALL AFFECT ANY RIGHT THAT HOLDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AGAINST
MAKER OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. MAKER AND HOLDER HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO
THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF
VENUE OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY COURT REFERRED TO IN THIS
SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, THE DEFENSE OF AN
INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT. EACH PARTY TO THIS AGREEMENT
IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 5 OF THIS NOTE. NOTHING IN THIS
AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY TO THIS AGREEMENT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

 

    	Restated Corporation Loan to Werner
	3 

    

    

 

Execution Copy

 

	 	Milton H Werner, PhD,
    an Individual
	 	 
	 	 
	 	By:	/s/ Milton H Werner      

  

	ACCEPTED AND AGREED TO:	 
	 	 
	Inhibikase Therapeutics,
    Inc.	 
	/s/ Elizabeth O'Farrell 	 
	Elizabeth O’Farrell	 
	Authorized Board Member	 

 

    	Restated Corporation Loan to Werner
	4Exhibit 4.12

 

WARRANT

 

THIS WARRANT AND THE SHARES ISSUABLE UPON
EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS, OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT
OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

 

 

Warrant To Purchase Common Stock

 

	Warrant No.: 11	Number of Shares: 21,854
	 	Warrant Exercise Price: $5.90 per share
	Issuance Date: August 25, 2020	Expiration Date: August 25, 2027

 

Inhibikase Therapeutics,
Inc., a Delaware corporation (the “Company”), hereby certifies that Flagship Consulting, Inc. (the “Holder”),
the registered Holder hereof or its permitted assigns, is entitled, subject to the terms set forth below, to purchase from the
Company upon surrender of this Warrant, at any time or times on or after the date hereof (the “Effective Date”),
but not after 11:59 P.M. Eastern Time on the Expiration Date (as defined herein), Twenty-one Thousand Eight Hundred Fifty-four
(21,854) fully paid and nonassessable shares of Common Stock (as defined herein) of the Company (the “Warrant Shares”)
at the exercise price per share of Five dollars and ninety cents ($5.90). Upon the written request of the Holder, the Company shall
promptly, but in no event later than three (3) Business Days following the receipt of such notice, confirm in writing to any such
Holder the number of shares of Common Stock available to purchase from the Company upon surrender of this Warrant. The Holder and
the Company agree that notwithstanding any terms to the contrary contained herein, the Holder shall have no right to exercise this
Warrant until the Effective Date. This Warrant, along with that certain other warrant entered into between the Holder and the Company
on the date hereof for 150,000 shares and that certain Amended and Restated Second Convertible Revolving Demand Promissory 2020
Note, collectively, are in full satisfaction of any rights to compensation the Holder has from the Company through the date hereof.

 

Section 1.              Definitions

 

(a)           The
following words and terms as used in this Warrant shall have the following meanings:

 

(i)          
“Affiliated Entity” means any general partner of a Person, if such Person is a partnership, or any person
or entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or in under common control
with, such Person.

 

(ii)         
“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in New
York City or the State of New York are authorized or required by law to remain closed.

 

     

     

    

 

(iii)           “Common
Stock” means (A) the Company’s Common Stock, par value $0.001 per share, and (B) any capital stock into which
such Common Stock shall have been changed or any capital stock resulting from a reclassification of such Common Stock.

 

(iv)          
“Effective Date” means August 25, 2020.

 

(v)           
“Expiration Date” means August 25, 2027.

 

(vi)          
“Fair Market Value” means, as of any particular date, the VWAP on the Trading Day immediately preceding
the date of the applicable Exercise Notice. If at any time the Common Stock is not listed or quoted for trading on any Trading
Market, the “Fair Market Value” of the Common Stock shall be the fair market value per share as determined by reference
to a valuation of the Common Stock performed within sixty (60) days prior to the applicable Exercise Notice by an independent valuation
firm engaged by the Company at its expense. The determination of such valuation firm shall be final and conclusive.

 

(vii)         
“Issuance Date” means August 25, 2020.

 

(viii)        “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.

 

(ix)           “Securities Act” means the Securities Act of 1933, as amended.

 

(x)            “Trading Day” means a day on which the Common Stock is traded on a Trading Market.

 

(xi)           “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed
or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq
Global Select Market or the New York Stock Exchange, OTCQB or OTCOX (or any successors to any of the foregoing).

 

(xii)          “VWAP” means, for any date, the daily volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg
L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)).

 

(xiii)         “Warrant” means this Warrant and all Warrants issued in exchange, transfer or replacement thereof.

 

(xiv)         “Warrant Exercise Price” shall be the price set forth on page one of this Warrant or as subsequently
adjusted as provided in Section 8 hereof.

 

(b)         Other Definitional
Provisions.

 

(i)             Except as otherwise specified herein, all references herein (A) to the Company shall be deemed to include the Company’s
successors and (B) to any applicable law defined or referred to herein shall be deemed references to such applicable law as the
same may have been or may be amended or supplemented from time to time.

 

    	 	2	 

     

    

 

(ii)            When
used in this Warrant, the words “herein”, “hereof”, and “hereunder” and
words of similar import, shall refer to this Warrant as a whole and not to any provision of this Warrant, and the words “Section”,
 “Schedule”, and “Exhibit” shall refer to Sections of, and Schedules and Exhibits to, this
Warrant unless otherwise specified.

 

(iii)           Whenever
the context so requires, the neuter gender includes the masculine or feminine, and the singular number includes the plural, and
vice versa.

 

Section 2.            Exercisability of Warrant.
The number of shares of Common Stock issuable pursuant to this Warrant are fully vested.

 

Section 3.            Exercise of Warrant.

 

(a)         Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder hereof then registered on the books
of the Company, in whole or in part, at any time on any Business Day on or after the opening of business on such Business Day,
commencing with the Effective Date, and prior to 11:59 P.M. Eastern Time on the Expiration Date, by (i) delivery of a written notice,
in the form of the subscription notice attached as Exhibit A hereto (the “Exercise Notice”), of such
Holder’s election to exercise this Warrant, which notice shall specify the number of Warrant Shares to be purchased which
shall not be less than 1,000 shares in each case (or if less than 1,000 shares are available to purchase from the Company pursuant
to this Warrant), such lesser amount (as such minimum number may be adjusted pursuant to Section 8), (ii) payment to the Company
of an amount equal to the Warrant Exercise Price(s) applicable to the Warrant Shares being purchased, multiplied by the number
of Warrant Shares (at the applicable Warrant Exercise Price) as to which this Warrant is being exercised (plus any applicable issue
or transfer taxes) (the “Aggregate Exercise Price”) in cash or wire transfer of immediately available funds
and (iii) the surrender of this Warrant (or an indemnification undertaking with respect to this Warrant in the case of its loss,
theft or destruction) to a common carrier for overnight delivery to the Company as soon as practicable following such date. Upon
delivery of the Exercise Notice and Aggregate Exercise Price referred to in clause (ii) above the Holder of this Warrant shall
be deemed for all corporate purposes to have become the Holder of record of the Warrant Shares with respect to which this Warrant
has been exercised. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of
the date the final Exercise Notice is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of
a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may
be less than the amount stated on the face hereof.

 

(b)         The
Company shall use best efforts to cause the Warrant Shares purchased hereunder to be transmitted by its transfer agent to the
Holder by crediting the account of the Holder’s broker with The Depository Trust Company through its Deposit or
Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system if there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the
Holder, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of
the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the
address specified by the Holder in the Notice of Exercise by the time and date that is no later than 11:00 am, Eastern time,
on the tenth (10th) Trading Day after the latest of (A) the delivery to the Company of the Notice of Exercise, (B) surrender
of this Warrant (if required) and (C) payment of the Aggregate Exercise Price (such date, the “Warrant Share
Delivery Date”). In no event may the Warrants be settled in cash. If there is no effective registration statement
permitting the resale of the Warrant Shares, then any Warrant Shares delivered upon exercise of this Warrant shall be
restricted shares. The Company has no obligation of any kind to register the Warrant Shares for resale. The Warrant Shares
shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to
have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment
to the Company of the Aggregate Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section
3(e) prior to the issuance of such shares, having been paid.

 

    	 	3	 

     

    

 

(c)          Unless the rights represented by this Warrant shall have expired or shall have been fully exercised, the Company shall,
as soon as practicable and in no event later than thirty (30) Business Days after any exercise and at its own expense, upon written
request of the Holder issue a new Warrant identical in all respects to this Warrant exercised except it shall represent rights
to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant exercised, less the
number of Warrant Shares with respect to which such Warrant is exercised.

 

(d)          No fractional Warrant Shares are to be issued upon any exercise of this Warrant, but rather the number of Warrant Shares
issued upon such exercise of this Warrant shall be rounded up or down to the nearest whole number.

 

(e)          Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such
Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that, in the event Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Warrant Power in the form attached hereto as Exhibit B duly executed by the Holder,
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto.

 

(f)          If at any time the Company proposes to merge or consolidate with or into any other corporation, effect any reorganization,
or sell or convey all or substantially all of its assets to any other entity, then, as a condition of such reorganization, consolidation,
merger, sale or conveyance, the Company or its successor, as the case may be, shall enter into a supplemental agreement to make
lawful and adequate provision whereby the Holder shall have the right to receive, upon exercise of this Warrant, the kind and amount
of equity securities which would have been received upon such reorganization, consolidation, merger, sale or conveyance by a Holder
of a number of shares of Common Stock equal to the number of shares issuable upon exercise of this Warrant immediately prior to
such reorganization, consolidation, merger, sale, or conveyance. The Company shall give the Holder of this Warrant ten (10) Business
Days’ prior written notice of the proposed effective date of any such merger, consolidation, reorganization, sale or conveyance,
and the Company shall also give the Holder of this Warrant ten (10) Business Days’ prior written notice of the commencement
of the Company’s voluntary or involuntary dissolution, liquidation or winding up. If the property to be received upon such
merger, consolidation, reorganization, sale or conveyance is not equity securities, and if this Warrant has not been exercised
by or on the effective date of such transaction, it shall terminate.

 

(g)         If,
at any time while this Warrant is outstanding, the Company declares or makes any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
 “Distribution”), then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common
Stock acquirable upon complete exercise of this Warrant immediately before the date of which a record is taken for such
Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
determined for the participation in such Distribution.

 

    	 	4	 

     

    

 

(h)         If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for, the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a “cashless exercise” in lieu of payment to the Company of the Aggregate Exercise
Price in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B)
(X)] by (A), where:

 

(A) = the Fair Market Value;

 

(B) = the Warrant Exercise Price,
as adjusted hereunder; and

 

(X) = the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.

 

If Warrant Shares are
issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities
Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised and the holding period of the Warrant
Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary
to this Section 3(h).

 

Section 4.             Covenants
as to Common Stock. The Company hereby covenants and agrees as follows:

 

(a)         This Warrant is duly authorized and validly issued.

 

(b)         All Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant will, upon issuance,
be validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof.

 

(c)         The Company will at all times have authorized and reserved at least one hundred percent (100%) of the number of shares of
Common Stock needed to provide for the exercise of the rights then represented by this Warrant and the par value of said shares
will at all times be less than or equal to the applicable Warrant Exercise Price.

 

(d)         The Company will not, by amendment of its Certificate of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed by it hereunder, but will at all times in good faith assist in the
carrying out of all the provisions of this Warrant.

 

    	 	5	 

     

    

 

Section
5.            Warrant Holder Not Deemed a
Stockholder. Except as otherwise specifically provided herein, no Holder, as such, of this Warrant shall be entitled to
vote or receive dividends or be deemed the holder of shares of capital stock of the Company for any purpose, nor shall
anything contained in this Warrant be construed to confer upon the Holder hereof, as such, any of the rights of a stockholder
of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of
stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which Holder is
then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be
construed as imposing any liabilities on such Holder to purchase any securities (upon exercise of this Warrant or otherwise)
or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

Section 6.             Representations
of Holder. The Holder of this Warrant, by the acceptance hereof, represents that it is acquiring this Warrant and the Warrant
Shares for its own account for investment only and not with a view towards, or for resale in connection with, the public sale or
distribution of this Warrant or the Warrant Shares, except pursuant to sales registered or exempted under the Securities Act; provided,
however, that by making the representations herein, the Holder does not agree to hold this Warrant or any of the Warrant Shares
for any minimum or other specific term and reserves the right to dispose of this Warrant and the Warrant Shares at any time in
accordance with or pursuant to a registration statement or an exemption under the Securities Act and other applicable securities
laws. The Holder of this Warrant further represents, by acceptance hereof, that, as of this date, such Holder is an “accredited
investor” as such term is defined in Rule 501(a)(1) of Regulation D promulgated by the Securities and Exchange Commission
under the Securities Act (an “Accredited Investor”). Upon exercise of this Warrant the Holder shall, if requested
by the Company, confirm in writing, in a form satisfactory to the Company, that the Warrant Shares so purchased are being acquired
solely for the Holder’s own account and not as a nominee for any other party, for investment, and not with a view toward
distribution or resale and that such Holder is an Accredited Investor. If such Holder cannot make such representations because
they would be factually incorrect, it shall be a condition to such Holder’s exercise of this Warrant that the Company receive
such other representations as the Company considers reasonably necessary to assure the Company that the issuance of its securities
upon exercise of this Warrant shall not violate any United States or state securities laws.

 

Section 7.            Ownership and Transfer.

 

(a)         The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate
by notice to the Holder hereof), a register for this Warrant, in which the Company shall record the name and address of the person
or entity in whose name this Warrant has been issued, as well as the name and address of each transferee. The Company may treat
the person in whose name any Warrant is registered on the register as the owner and Holder thereof for all purposes, notwithstanding
any notice to the contrary, but in all events recognizing any transfers made in accordance with the terms of this Warrant.

 

(b)         The
Company agrees that, subject to the satisfaction of the conditions set forth in this Section 7(b), the Holder shall be
entitled to transfer all or any portion of this Warrant or of the Warrant Shares (i) in the case that the Holder is an
incorporated or other entity, to an Affiliated Entity of the Holder or (ii) in the case that the Holder is a natural person,
for bona fide estate planning purposes, either during his or her lifetime or on death by will or intestacy to his or her
spouse, child (natural or adopted), or any other direct lineal descendant of such Holder (or his or her spouse) (all of the
foregoing collectively referred to as “family members”), or to any custodian or trustee of any trust,
partnership or limited liability company for the benefit of, or the ownership interests of which are owned wholly by, such
Holder or any such family members. The Holder agrees not to make any transfer or disposition of the Warrant or all or any
portion of the Warrant Shares to any Affiliated Entity, family member or custodian or trustee or to any other Person unless
and until (i) the Holder shall have notified the Company of the proposed disposition and shall have furnished the Company
with a reasonably detailed statement of the circumstances surrounding the proposed disposition and (ii) the transferee has
agreed in writing for the benefit of the Company to be bound by the terms of this Warrant and any other stockholder or
similar agreement among substantially all other holders of Common Stock as reasonably requested by the Company. Any transfer
in violation of this Section 7(b) shall be void ab initio.

 

    	 	6	 

     

    

 

Section 8.             Adjustment
of Warrant Exercise Price and Number of Shares. The Warrant Exercise Price and the number of shares of Common Stock issuable
upon exercise of this Warrant shall be adjusted from time to time as follows:

 

(a)          Adjustment
of Warrant Exercise Price upon Subdivision or Combination of Common Stock. If the Company at any time after the date of issuance
of this Warrant subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding
shares of Common Stock into a greater number of shares, any Warrant Exercise Price in effect immediately prior to such subdivision
will be proportionately reduced and the number of shares of Common Stock obtainable upon exercise of this Warrant will be proportionately
increased. If the Company at any time after the date of issuance of this Warrant combines (by combination, reverse stock split
or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, any Warrant Exercise
Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares issuable
upon exercise of this Warrant will be proportionately decreased. Any adjustment under this Section 8(a) shall become effective
at the close of business on the date the subdivision or combination becomes effective.

 

(b)         Notices.
Promptly upon any adjustment of the Warrant Exercise Price, the Company will give written notice thereof to the Holder of this
Warrant, setting forth in reasonable detail, and certifying, the calculation of such adjustment.

 

Section 9.            Mutilated
or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company shall promptly, on receipt of an
indemnification undertaking (or, in the case of a mutilated Warrant, the Warrant), issue a new Warrant of like denomination and
tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

Section 10.          Notice.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Warrant must be
in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of receipt is received by the sending party transmission is mechanically or electronically
generated and kept on file by the sending party); or (iii) one Business Day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such
communications shall be:

 

		If to Holder:	Flagship Consulting, Inc.

131 Daniel Webster Highway

Suite 322

Nashua, NH 03060

Attn: Joseph Frattaroli

 

		If to the Company, to:	Inhibikase Therapeutics, Inc.

3350 Riverwood Parkway,

Suite 1900

Atlanta, GA 30339

Attn: Milton Werner, Ph.D.

President and CEO

 

    	 	7	 

     

    

 

Each party shall provide five days’
prior written notice to the other party of any change in address or facsimile number. Written confirmation of receipt (A) given
by the recipient of such notice, consent, facsimile, waiver or other communication, or (B) provided by a nationally recognized
overnight delivery service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally
recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

 

Section 11.          Date.
The date of this Warrant is set forth on page 1 hereof. This Warrant, in all events, shall be wholly void and of no effect after
the close of business on the Expiration Date.

 

Section 12.          Amendment
and Waiver. Except as otherwise provided herein, the provisions of the Warrants may be amended by a writing executed by both
the Company and the Holder.

 

Section 13.          Descriptive
Headings; Governing Law. The descriptive headings of the several sections and paragraphs of this Warrant are inserted for convenience
only and do not constitute a part of this Warrant. All questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be governed by the internal laws of the State of Delaware, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in Delaware, for the adjudication of any dispute hereunder or in connection herewith or
therewith, or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Warrant and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.

 

Section 14.         Waiver
of Jury Trial. AS A MATERIAL INDUCEMENT FOR EACH PARTY HERETO TO ENTER INTO THIS WARRANT, THE PARTIES HERETO HEREBY WAIVE
ANY RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING RELATED IN ANY WAY TO THIS WARRANT AND/OR ANY AND ALL OF THE OTHER DOCUMENTS
ASSOCIATED WITH THIS TRANSACTION.

 

Section 15.          Lock-Up
Agreement. If requested by the Company and the representative underwriter, Holder agrees to enter into a lock-up agreement
(the “Lock-Up Agreement”) pursuant to which it will not, for a period set forth in the Lock-up Agreement following
the effective date of the first registration statement of the Company’s initial public offering, offer, sell or otherwise
dispose of the Warrant Shares or any other equity securities of the Company held. The Lock-up Agreement shall provide that the
provisions thereof may be waived with the consent of the Company and the representative underwriter.

 

[signature page follows]

 

    	 	8	 

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be signed as of the date first set forth above.

 

 

	Flagship Consulting, Inc.	 	Inhibikase Therapeutics, Inc.
	 	 	 
	 	 	 	 	 
	By:	/s/ Joseph Frattaroli	 	By:	/s/ Milton Werner
	Name:	Joseph Frattaroli	 	Name:	Milton Werner, Ph.D.
	Title:	Authorized Officer	 	Title:	President & Chief Executive Officer

 

    	 	9	 

     

    

 

EXHIBIT A TO WARRANT

 

EXERCISE NOTICE

 

TO BE EXECUTED

BY THE REGISTERED HOLDER TO EXERCISE THIS WARRANT

 

 

 

The undersigned Holder hereby exercises
the right to purchase____________ shares of Common Stock (“Warrant Shares”) of Inhibikase Therapeutics, Inc.,
a Delaware corporation (the “Company”), evidenced by the attached Warrant (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

1.           
Form of Warrant Exercise Price and Payment. Check applicable box:

 

  ̈
The Holder intends that payment of the Warrant Exercise Price shall be made as a “Cash Exercise” with respect to
______________ Warrant Shares. The Holder shall pay the sum of $______________ to the Company in accordance with the terms of
the Warrant.

 

  ̈
The Holder intends that payment of the Warrant Exercise Price shall be made as a “Cashless Exercise” in
accordance with the formula set forth in Section 3(h), to exercise this Warrant with respect to the maximum number of Warrant
Shares purchasable pursuant to the procedure set forth in Section 3(h).

 

2.            Delivery
of Warrant Shares. The Company shall deliver to the Holder_______________ Warrant Shares in accordance with the terms of
the Warrant and will issue said Warrant Shares in the name of the undersigned or in such other name or names as is specified
below:

 

The Warrant Shares shall be delivered to the following
DWAC Account Number:

 

 

[SIGNATURE OF HOLDER:]

 

Name of Holder:_________________________________________

 

Signature of Authorized Signatory:___________________________

 

Name of Authorized Signatory:________________________

 

Title of Authorized Signatory:_________________________

 

Date:_________________________________________________

 

    	 	A-1	 

     

    

 

EXHIBIT B TO WARRANT

FORM OF WARRANT POWER

 

FOR VALUE RECEIVED,
the undersigned does hereby assign and transfer to ________________, Federal Identification No.__________, a warrant to purchase
____________ shares of the capital stock of Inhibikase Therapeutics, Inc., a Delaware corporation, represented by warrant certificate
no. _____, standing in the name of the undersigned on the books of said corporation. The undersigned does hereby irrevocably
constitute and appoint ______________, attorney to transfer the warrants of said corporation, with full power of substitution in
the premises.

 

	Dated:	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

    	 	B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]